课题基金 / 基金详情

PHARMACOKINETICS OF SCH39166 IN SUBJECTS W/ CHRONIC LIVER DISEASE

PHARMACOKINETICS OF SCH39166 IN SUBJECTS W/ CHRONIC LIVER DISEASE
SCH39166 在慢性肝病受试者中的药代动力学
批准号：
6265601
负责人：
STEVEN SCHENKER
金额：
$1.64万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265601
关键词：
chronic disease /disorder clinical research clinical trials cocaine dopamine antagonists dopamine receptor endogenous opioid human subject human therapy evaluation liver disorder liver disorder chemotherapy liver function neural transmission neuropharmacology nicotine pharmacokinetics substance abuse related disorder

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SCH39166 is a selective antagonist of dopamine D1 and D5 receptors. Dopamine neurotransmission is stimulated by all addictive drugs and even highly palatable food. But the addictive properties of drugs such as cocaine, nicotine, opiates and ethanol appear to be associated with dopamine stimulation of D1 and/or D5 receptors. Since SCH39166 is extensively glucuronidated in humans, it is clinically relevant to study the effects of various degrees of altered hepatic function on the pharmacokinetics of the drug -- especially in light of the prevalence of hepatic disease in substance-addicted persons. The primary objective of this single dose study is to evaluate and compare the pharmacokinetics of SCH39166 in subjects with normal liver function and with various degrees of stable chronic liver disease. Data from this study will be used to develop dosing guidelines for patients with various degrees of chronic liver disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金